

# PRODUCT INFORMATION



## LipidLaunch™ ALC-0315 LNP (GFP)



Item No. 40105

### Overview and Properties

**Ex./Em. Max:** 488/507 nm  
**Storage:** -80°C (as supplied)  
**Stability:** ≥9 months  
**Supplied in:** TBS, with 10% sucrose

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Images



LNP Characterization Parameters	
Size	75-150 nm
Polydispersity index (PDI)	<0.2
Encapsulation efficiency (%EE)	>85%
mRNA concentration	Batch specific, 25-100 µg/ml
mRNA/vial	5 µg

Transfection of cells with GFP-encapsulating ALC-0315 particles. Huh7 hepatocytes (left) and A549 lung epithelial cells (right) were incubated with Cayman's LipidLaunch™ ALC-0315 LNP (GFP) (Item No. 40105) at an RNA concentration of 500 and 250 ng/ml, respectively, for 24 hours in cell culture media with 10% FBS. Cells were stained with 4 µM Hoechst 33342 (Item No. 15547) and imaged using 465 LED/GFP and 365 LED/DAPI cubes on a BioTek Cytation 5 imaging plate reader.

### Description

LipidLaunch™ ALC-0315 LNP (GFP) is a solution containing lipid nanoparticles (LNPs) composed of the ionizable cationic amino lipid ALC-0315 (Item No. 34337), cholesterol (Item No. 9003100), 1,2-distearoyl-*sn*-glycero-3-PC (1,2-DSPC; Item No. 15100), and the lipid excipient ALC-0159 (Item No. 34336) at a molar ratio of 46.3:42.7:9.4:1.6 and encapsulating mRNA encoding the fluorescent protein GFP. It is intended for proof-of-concept experiments to determine whether ALC-0315-based LNPs can effectively lead to the expression of a protein of interest in a target cell type, either *in vitro* or *in vivo*. GFP has excitation/emission maxima of 488/507 nm, respectively.

**Suggested *in vitro* use:** Thaw LNPs on ice with occasional gentle swirling (*do not vortex*). Using a gentle pipetting technique, dilute 1:100-1:500 in complete cell culture media (with serum) and add to subconfluent adherent cells in a fluorescence imaging-compatible tissue culture plate. Expression of GFP may be detectable as early as six hours after treatment. Optimal conditions are highly dependent on cell type.

WARNING  
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA  
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY  
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/28/2026

CAYMAN CHEMICAL  
1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA  
PHONE: [800] 364-9897  
[734] 971-3335  
FAX: [734] 971-3640  
CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM